This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
by Zacks Equity Research
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
AMAG Pharmaceuticals (AMAG) Down 3.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMAG's Label Expansion of Lead Products Raises Share Price
by Zacks Equity Research
AMAG's (AMAG) label expansion efforts for Feraheme and Makena are encouraging.
AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
by Zacks Equity Research
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 0.00% and 3.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Investors are looking forward to Novavax's (NVAX) updates on its pipeline candidates when it reports third-quarter 2018 results.
Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBiX) updates on its pipeline candidates when it reports third-quarter results.
Will Cigna (CI) Q3 Earnings Gain on Revenue Growth?
by Zacks Equity Research
Cigna (CI) Q3 earnings should gain from revenue and membership growth
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
We expect CRISPR (CRSP) to provide updates on its pipeline candidates in the third quarter of 2018.
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings
by Zacks Equity Research
We take a look at a few stocks that might deliver an earnings beat when they report next week.
AMAG Pharmaceuticals (AMAG) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) diversified product portfolio, global footprint and productive R&D should help drive both top-and bottom-line growth in the third quarter of 2018.
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Let's look at the factors that will impact Alexion's (ALXN) third -quarter 2018 earnings scheduled to release on Oct 24.
Is the Options Market Predicting a Spike in AMAG Pharmaceuticals (AMAG) Stock?
by Zacks Equity Research
Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.
New Strong Sell Stocks for October 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
AMAG In-Licenses Global Rights to Orphan Drug Candidate
by Zacks Equity Research
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.
Options Traders Expect Huge Moves in AMAG Pharmaceuticals (AMAG) Stock
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) needs investors to pay close attention to the stock based on moves in the options market lately.
AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -257.14% and -6.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
by Zacks Equity Research
AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.
AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
AMAG Pharma (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.
Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February
by Arpita Dutt
Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
by Zacks Equity Research
TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.